

What's New? Update on Experimental Agents

March 8, 2007



AIDSmeds founder Peter Staley interviewed Dr. Calvin Cohen, research director of the Community Research Initiative of New England, about new drugs in the pipeline that might help treatment-experienced patients needing new options. Hear the latest news about Isentress and elvitegravir, two integrase inhibitor, maraviroc, a CCR5 inhibitor, and TMC-278, a new non-nuke.

Double click for the full interview (14 minutes):

Content no longer available

Or hear part I about [Isentress](#), Merck's new integrase inhibitor (4 minutes):

Content no longer available

Or hear part II about [elvitegravir](#), Gilead's new integrase inhibitor (2 minutes):

Content no longer available

Or hear part III about [maraviroc](#), Pfizer's new CCR5 inhibitor (5 minutes):

Content no longer available

Or hear part IV about [TMC-278](#), Tibotec's new non-nuke (3 minutes):

Content no longer available

Or [click here](#) to read the full transcript of the interview.
